VolitionRX (VNRX) AI Stock Analysis

• Market Cap: $53.50M
• Dividend Yield: N/A
• Average Volume (3M): 837.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.40
• Revenue Growth: 35.10%
• EPS Growth: 39.15%
• Country: US
• Employees: 85
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.06
• Shares Outstanding: 119,145,424
• 10 Day Avg. Volume: 1,018,879
• 30 Day Avg. Volume: 837,654
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.60
• Enterprise Value/Revenue: 64.75
• Enterprise Value/Gross Profit: 64.75
• Enterprise Value/Ebitda: -3.98
• 1Y Price Target: $2.50
• Price Target Upside: 455.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $0.50 ▲(11.11% Upside)

VolitionRX's overall stock score is primarily impacted by its weak financial performance, characterized by negative profitability and cash flow issues. Technical analysis further indicates bearish trends, while valuation metrics are poor due to ongoing losses. The earnings call provided some positive developments, but concerns about revenue predictability and cash reserves remain significant.

Positive Factors

Revenue Growth

The 15% revenue growth and first sales of Nu.Q NETs demonstrate VolitionRx's expanding market presence and product adoption, supporting long-term revenue potential.

Cost Reduction

Significant cost reductions improve operational efficiency, enhancing profitability potential and financial sustainability over the long term.

Strategic Partnerships

Strong progress in securing strategic partnerships and licensing agreements can drive future revenue streams and enhance competitive positioning.

Negative Factors

Cash Reserves Decrease

Decreasing cash reserves limit financial flexibility and may hinder the company's ability to invest in growth opportunities or weather financial challenges.

Negative Profit Margins

Persistent negative profit margins indicate ongoing challenges in achieving profitability, which can impact long-term financial health and investor confidence.

Uncertain Revenue Projections

Uncertain revenue projections create challenges in financial planning and investor expectations, potentially affecting the company's market valuation.

VolitionRX Business Overview & Revenue Model

Company Description

VolitionRx Limited (VNRX) is a biotechnology company focused on developing blood-based diagnostic tests for cancer detection and monitoring. The company operates primarily in the healthcare sector, utilizing its proprietary Nucleosomics™ technology to identify cancer-related biomarkers in the blood. VolitionRx aims to provide accurate, easy-to-use, and cost-effective diagnostic solutions that can improve patient outcomes through early detection and monitoring of cancer.

How the Company Makes Money

VolitionRx generates revenue primarily through the sale of its diagnostic tests and services. The company is working on commercializing its tests, which are intended for use in a variety of cancer types, including colorectal cancer. Key revenue streams include partnerships with laboratories and healthcare providers that utilize VolitionRx's tests in their diagnostic offerings. Additionally, the company may generate revenue through collaborations with pharmaceutical companies for research and development purposes, as well as potential licensing agreements. Significant partnerships with established medical institutions and ongoing clinical trials further enhance its revenue potential.

VolitionRX Financial Statement Overview

Summary

VolitionRX is experiencing significant financial difficulties across all major financial statements. The income statement shows persistent losses despite modest revenue growth. The balance sheet highlights critical solvency issues with negative equity and high liabilities. Lastly, the cash flow statement indicates a heavy reliance on financing to maintain liquidity. These factors collectively suggest a high-risk financial profile, necessitating strategic improvements in revenue generation and cost management to stabilize the company's finances.

Income Statement

VolitionRX's income statement reveals a challenging financial position with consistent net losses. The gross profit margin remains positive at 100% due to low revenue, while net profit margins are significantly negative due to large operating expenses. The revenue growth shows a positive trajectory, increasing by approximately 6.1% in the TTM, yet the company struggles with substantial negative EBIT and EBITDA margins, indicating high operational costs relative to revenue.

Balance Sheet

The balance sheet presents a precarious financial situation with negative stockholders' equity, suggesting the company is heavily leveraged. The debt-to-equity ratio cannot be calculated due to negative equity, but this signifies high financial risk. Total liabilities significantly exceed total assets, indicating potential solvency issues. The low equity ratio further supports the company's weak financial position.

Cash Flow

Cash flow analysis shows VolitionRX faces substantial negative free cash flow, although free cash flow did improve slightly from the previous year. The operating cash flow remains negative, indicating insufficient cash generation from operations to cover expenses. Financing activities have been a primary source of cash, suggesting dependency on external funding to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.32M	1.23M	775.30K	306.39K	90.03K	13.43K
Gross Profit	1.32M	1.23M	775.30K	-882.03K	90.03K	13.43K
EBITDA	-21.48M	-25.62M	-34.04M	-29.24M	-25.69M	-19.23M
Net Income	-23.32M	-26.97M	-35.32M	-30.27M	-26.97M	-20.48M
Balance Sheet
Total Assets	8.70M	9.40M	27.95M	18.30M	27.49M	26.15M
Cash, Cash Equivalents and Short-Term Investments	2.26M	3.26M	20.73M	10.87M	20.58M	19.44M
Total Debt	10.94M	5.82M	5.86M	4.97M	4.02M	4.44M
Total Liabilities	41.80M	35.51M	36.66M	21.42M	9.77M	9.86M
Stockholders Equity	-31.82M	-24.91M	-7.80M	-2.57M	17.94M	16.34M
Cash Flow
Free Cash Flow	-21.79M	-26.47M	-19.15M	-16.85M	-21.83M	-18.41M
Operating Cash Flow	-21.38M	-25.89M	-18.06M	-15.28M	-20.85M	-16.46M
Investing Cash Flow	-413.19K	-573.85K	-1.08M	-1.57M	-973.56K	-1.65M
Financing Cash Flow	17.23M	8.66M	28.98M	6.94M	22.86M	20.62M

VolitionRX Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VNRX, the sentiment is Negative. The current price of 0.45 is below the 20-day moving average (MA) of 0.46, below the 50-day MA of 0.56, and below the 200-day MA of 0.59, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 40.75 is Neutral, neither overbought nor oversold. The STOCH value of 42.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VNRX.

VolitionRX Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRPO	55 Neutral	$32.51M	-16.60	-14.76%	―	27.05%	55.03%
BNR	55 Neutral	$121.79M	-6.04	-22.66%	―	5.33%	75.52%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BDSX	45 Neutral	$60.46M	-1.42	-302.55%	―	25.70%	39.25%
VNRX	43 Neutral	$53.50M	―	―	―	35.10%	39.15%
BNGO	41 Neutral	$16.58M	-0.04	-118.26%	―	-25.02%	85.08%
TRIB	40 Underperform	$18.05M	-0.34	―	―	-4.40%	-6.31%

VolitionRX Corporate Events

VolitionRx Ltd. Earnings Call: Key Insights and Challenges

VolitionRx Ltd.’s recent earnings call conveyed a mixed sentiment, highlighting significant achievements in cost reduction, revenue growth, and product sales, alongside promising clinical study outcomes. The company also made notable strides in licensing and partnerships. However, concerns were raised regarding uncertain revenue projections and dwindling cash reserves.

VolitionRx Reports Q2 2025 Financial Results and Strategic Progress

VolitionRx Limited, a multi-national epigenetics company, is dedicated to advancing the science of epigenetics through the development of simple, cost-effective blood tests for early detection and monitoring of diseases, including cancer and sepsis.